Hypodopaminergic polygenic risk for polysubstance use by Pasman, J.A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/175577
 
 
 
Please be advised that this information was generated on 2019-06-01 and may be subject to
change.
J Psychol Cognition 2017 Volume 2 Issue 2 138
http://www.alliedacademies.org/journal-of-psychology-and-cognition/Research Article
Introduction
In the Netherlands, about 25% of the population older than 
twelve is a current smoker, 77% is a current alcohol drinker, 
and 20% has used cannabis at least once [1], which is largely 
in line with prevalence estimates from developed countries 
worldwide [2-4]. Factors that influence whether an individual 
(ab)uses a substance have been found to be shared across 
different substances and across moderate and problematic use 
patterns [5]. 
Genetic predisposition may be such a shared vulnerability 
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Abstract
Twin studies have shown substantial heritability for polysubstance use. Previous research has 
sought to pinpoint this genetic influence to variants in genes related to dopamine signaling, 
that are known to lower baseline dopamine levels (hypodopaminergic function). Candidate-
gene studies often used single-gene designs and have yielded inconsistent results. Genome-wide 
association studies mainly include Single Nucleotide Polymorphisms (SNPs). In this study, a 
risk score was calculated based on both SNPs as well as Variable Number of Tandem Repeats 
(VNTRs).
Survey data on nicotine, alcohol and cannabis use from two family samples were analysed 
(N=2435 and N=1173). Moderate and problematic polysubstance uses were explored. A polygenic 
risk score was calculated by averaging the number of hypodopaminergic variants in three 
polymorphisms. Polysubstance use was regressed on this score with sex and age as covariates. 
Power was sufficient to detect small effect sizes (R2=0.4-0.8%).
The hypodopaminergic polygenic risk score (HPRS) was not related to polysubstance use in 
either sample. There were some indications for opposing effects of individual polymorphisms 
and separate substance use outcomes and for an interaction of the polygenic risk score with 
education level. There were no effects of a score extended with extra polymorphisms, and there 
were no quadratic effects of the HPRS.
The HPRS did not predict polysubstance use. Several explanations for these findings were ruled 
out. Future research might employ more comprehensive genetic models, thereby including gene-
environment interaction.
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factor. Twin models show that the genetic factors underlying 
nicotine, alcohol, and cannabis use overlap to a large extent 
[6]. Molecular genetic studies show that variants associated 
with the use of one substance also show a relation with the use 
of other substances, at least when looking at the same stage 
of use. For example, there are substantial genetic correlations 
between smoking initiation and cannabis initiation and 
between glasses of alcohol per week and number of cigarettes 
per day [7]. Likewise, genetic risk factors for smoking 
quantity predicted drinking quantity [8]. Therefore, it is 
sensible to look at multiple substances concurrently when 
considering the etiology of substance use.
Dopamine-mediated vulnerability to substance use
Traditional candidate-gene studies have sought to pinpoint 
the genetic influence in substance use at dopamine-related 
genes. These genes are considered plausible candidates, 
because of the function of dopamine in the brain’s reward 
system. Addictive substances enhance levels of dopamine, 
resulting in feelings of pleasure [9,10]. According to the 
reward deficiency hypothesis some individuals are more 
prone to substance use than others because of differences 
in dopamine function. It has been proposed that individuals 
with lower baseline dopamine levels are more easily ‘bored’ 
and will seek more stimulation in order to experience the 
rewarding effects of dopamine [11,12]. Indeed, results from 
PET studies suggest lower dopamine receptor availability, 
receptor binding, and release in substance abusers than in 
controls [13].
These lower homeostatic dopamine levels may be caused 
by variations in dopamine-related genes. For example, 
alleles related to deficient dopamine reception (such as 
TaqI A1 in DRD2) might lead to lower basal dopamine 
(‘hypodopaminergic) function and thus to lower reward 
sensitivity, which might then elicit substance-seeking behavior 
[14]. Many similar hypodopaminergic polymorphisms 
have been implicated in substance use. Importantly, a large 
proportion of those polymorphisms are not Single Nucleotide 
Polymorphisms (SNPs) but Variable Number of Tandem 
Repeats (VNTRs). Whereas a SNP is a variation of only one 
nucleotide, VNTRs are variations in the length of a repeat 
sequence of larger units of DNA. Genome-Wide Association 
Studies (GWAS), which look for an association between 
genetic variation and a given phenotype, have as of yet not 
included VNTRs. 
Hypodopaminergic polygenic risk score
As a reflection of dopamine-related genetic vulnerability 
to substance use, this study will use a genetic risk score for 
hypodopaminergic functioning. Variations in dopamine-
related genes may lead to individual differences in basal 
dopamine levels, for example by influencing the number of 
dopamine receptors. These genes all have a small contribution, 
so considering them together is a more powerful method 
for identifying genetic risk than a single-gene approach. 
Although other recent studies have used polygenic risk 
scores in predicting substance use [8], these generally did not 
include non-SNP variations. 
To the best of our knowledge, only two studies have 
used a sum score of risk alleles for substance use combining 
both SNPs and VNTRs. One study looked at the number of 
alleles associated with hypodopaminergic function and found 
this number to be associated with the use of licit and illicit 
substances in adolescent males [15]. In contrast, Davis and 
Loxton [16] used a score of similar variants, but found that 
alleles associated with higher dopamine levels predicted 
behavioral and substance addiction. These conflicting 
results might be due to differences in outcome, the exact 
polymorphisms under study and importantly, in the choice 
for which allele of each variant was considered as the risk 
allele.
For the current study, the literature was therefore 
carefully examined in order to make an informed prediction. 
Well-studied polymorphisms with a clear implication in 
dopamine function and substance use were included. Many 
studies showing a relation between these polymorphisms and 
substance use could be identified, of which representative 
examples are given in Table 1. However, conflicting studies 
were identified as well (Table 1), underlining the need for 
more powerful tests of those associations. Most studies 
identified alleles associated with low dopamine function as 
conferring risk for substance use, which is in line with the 
reward deficiency hypothesis. Thus, for the current study, we 
counted the number of alleles associated with low dopamine 
Gene Polymorphism Risk allele Dopamine-related effect of risk allele
Representative literature examples
Supportive Opposing
DAT1
dopamine transporter gene
3’ UTR 40-bp 
VNTR
10R Enhanced clearance
Smoking: Laucht et al. [52]; Herman 
et al. [53].
Alcohol: Schacht et al. [54]
Drugs: Stolf et al. [55]
Smoking: Munafo et al. [56] 
Substance abuse: Blum et al. [14] 
Polydrug use: Conner et al. [15]
DRD2
dopamine receptor D2 gene
rs1800497 TaqIA 
SNPa T
Reduced D2 receptor 
density
Smoking: Munafo, et al. [57] 
Alcohol: Smith et al. [58]
Drugs: Esposito-Smythers et al. [59]
Alcohol: Hallikainen et al. [60]
DRD4
dopamine receptor D4 gene
3rd exon 48-bp 
VNTR
long (>=7 
repeats)
Reduced receptor 
efficiency
Addiction: McGeary [61] 
Substance use: Olsson et al. [62]
Addiction: Comings et al. [63]
A supportive research finding indicates that a positive relation was found between the risk allele and substance use; an opposing finding 
indicates a positive relation between the non-risk allele and substance use
aThis polymorphism was previously thought to lie in the DRD2 gene but is actually located in the ankyrin repeat and kinase domain containing 
1 (ANKK1) gene next to DRD2
Table 1. Overview of polymorphisms in dopamine-related genes included in the hypodopaminergic polygenic risk score.
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for our genetic risk score. Although the number of selected 
polymorphisms is limited, previous polygenic risk score 
studies have successfully predicted phenotypes using a score 
of only a few variants [17-21]. Because heritability is likely 
to be overlapping for different substances, and because it 
appears from the literature that the same variants are implied, 
it is hypothesized that reward-related polymorphisms form a 
liability factor common to different substance use phenotypes. 
Thus, we predict that hypodopaminergic genetic risk predicts 
higher chances of having initiated use of multiple substances.
Materials and Methods
To test whether hypodopaminergic polygenic risk would 
predict polysubstance use, data of two independent family 
samples were utilized.
NTR sample
Participants: The first sample included participants 
from the Netherlands Twin Register (NTR), an ongoing 
longitudinal study of twins and their family members. A 
detailed description of study methods has been provided 
elsewhere [22]. Data on substance use were collected between 
1991 and 2014 in nine waves. For a subsample there were also 
data on SNPs and VNTRs (Figure 1). Because of the family 
structure in the sample, age had a bimodal distribution, with 
a mean of M=22.1 (SD=3.0, N=1139) and M=47.1 (SD=11.2, 
N=1296). Females made up 62.8% of the sample. 
Genotype data: NTR participants have been genotyped 
for common SNPs and VNTRs using procedures described 
elsewhere [22,23]. The hypodopaminergic polygenic risk 
score (HPRS) was the average number of risk alleles in 
the three variants. Individuals with more than one missing 
genotype were excluded (N=58). The formula for this 
procedure was: 
( )101 2 4, , R T long
v
DAT DRD DRD
HPRS
N
=
∑
where, the numerator counts the risk alleles (0,1 or 2 
per genetic variant) and the denominator Nv is the number 
of genotyped variants (minimal two). Thus, the HPRS 
reflects the mean number of risk alleles for each individual. 
The variants were not weighted by previously found effect 
sizes (as is common for polygenic risks score studies), since 
GWAS on which such weighting procedures are based have 
not included VNTRs. Principal components for genetic 
ancestry were not used to control for population stratification, 
as required data were not available for all NTR participants 
and no such data were available in the F&H sample. Non-
Caucasian individuals were excluded from analysis (N=177) 
and individuals with no information on ethnicity (N=663) 
were kept in the analyses (results did not change when they 
were excluded; data not shown). The data met quality criteria 
for minor allele frequency (MAF>0.05), Hardy-Weinberg 
disequilibrium (H-W, threshold p>0.001) and Mendelian 
errors (<0.02 per variant).
F&H sample
Participants: The second sample included participants 
from the Dutch longitudinal Family and Health (F&H) study. 
Details on the F&H sample and procedures are provided 
elsewhere [24,25]. The sample consisted of families of two 
children and both their parents (N=428 families). Survey data 
were collected between 2002 and 2009 in six yearly waves. 
DNA was collected for 1265 individuals between 2006 and 
2007 via saliva sampling (Figure 1). 
Mean age was 19.0 (SD=0.8) years for the child cohort 
(N=621) and 49.8 (SD=3.7) years for the parent cohort 
(N=551). About half of the sample was female (49.4%). 
Genotype data: Individual variants were genotyped using 
polymerase chain reaction [26]. The HPRS again comprised 
the mean number of risk alleles in the DAT1, DRD4 and DRD2 
genes. Individuals born outside of Europe were excluded 
(N=15). Persons with missing birth country were included 
(N=61; results did not change when these individuals were 
not considered; data not shown). The genotype variables 
withstood MAF (>0.05) and Hardy-Weinberg quality control 
(p>0.001).
Measures
Moderate substance use 
Similar survey items were used to determine moderate 
substance use in both samples. Moderate polysubstance use 
was defined as having done at least two of the following: 1) 
smoked daily; 2) drank at least one glass of alcohol per day; 
3) ever used cannabis (Table 2). In the F&H sample, cannabis Figure 1. Data availability. Flowchart of data availability in the 
NTR (left) and F&H sample (right).
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use was only measured in adolescents. No distinction was 
made between using substances concurrently or at different 
time points, so that an ex-smoker who currently drank 
alcohol was in the same category as someone who both drank 
and smoked currently. We expect that using such a composite 
will enhance power to detect effects, as it measures initiation 
of use of multiple substances, and will serve the purpose of 
capturing genetic variance common to different substance 
use phenotypes.
Problematic substance use
For smoking, in both samples the Fagerström Test of 
Nicotine Dependence (FTND) was used. The 6-item FTND 
measures the degree of nicotine dependence [27]. The Dutch 
version of this questionnaire has shown sufficient reliability 
and validity [28]. 
For drinking, the 4-item CAGE questionnaire was used in 
the NTR sample, and the short version of the Rutgers Alcohol 
Problems Index (RAPI) was used in the F&H sample. 
CAGE is an acronym for the four items in the questionnaire: 
feeling you need to cut down on drinking; feeling annoyed 
by people criticizing your drinking; feeling Guilty about 
drinking; and using alcohol as an Eye-opener to wake up in 
the morning [29]. The Dutch version has shown sufficient 
quality [30]. The common cut-off score of 2 has shown to 
yield good specificity and sensitivity [31]. The RAPI is a 
longer instrument aimed at measuring problematic use, and 
includes items similar to the CAGE, such as ‘was told by 
a friend, neighbor or relative to stop or cut down drinking’ 
[32]. The shortened 18-item version correlates highly with 
the original version, which has good measurement properties 
[33]. Previous studies used a cut-off total score of >=15 for 
the 23-item version to classify persons as problematic users 
[34-36], which corresponds to a >=12 cut-off for the 18-item 
version. Although they are different instruments, the RAPI 
and CAGE show overlap [37]. 
In both samples problematic cannabis use was determined 
based on a question of the format ‘Have you ever started 
using cannabis on a regular basis?’ In the F&H sample, this 
information was only available for adolescents. A person was 
considered a problematic polysubstance user when he/she 
had met at least two of the following criteria on at least one 
measurement moment: 1) score above cut-off for the FTND; 
2) score above cut-off for the CAGE/ RAPI; 3) regular use 
of cannabis. 
Statistical analyses
A logistic generalized estimating equations (GEE) 
model was used to examine the relationship between the 
hypodopaminergic polygenic risk score and polysubstance 
use. GEE is a form of multilevel regression with the 
possibility to control for (family) clustering. Separate 
analyses were conducted for both outcome measures and for 
both samples. Age and sex were included as covariates in the 
analyses. Birth cohort (being a parent or a child in the family) 
correlated almost perfectly with age and was not included in 
the model. Continuous variables were centered on the sample 
mean.
Power 
In Figure 2 power calculations are depicted for both 
samples. Effect sizes of individual genetic variants are 
commonly found to be between R2=0.1 to 1% [38,39]. In the 
current investigation, an R2 of 0.3-3% might thus be expected, 
NTR F&H
Composites Based on measures Descriptive Based on measures Descriptive 
HPRS
mean number of risk 
alleles
DAT1, DRD4, DRD2
N=2435
M=0.81
SD=0.38
DAT1, DRD4, DRD2
N=1172
M=0.76 
SD=0.34
eHPRSb
mean number of risk 
alleles
DAT1, DRD4, DRD2, DRD5, MAOA, 
OPRM1, COMT
N=1771
M=1.01
SD=0.24
DAT1, DRD4, DRD2, OPRM1
N=1122
M=1.02
SD=0.27
Moderate poly use
At least two substances 
used over time
>=1 cigarette per dayc
>=6 glasses alcohol per week & 
>=drinking a few times per weekd
ever use of cannabis
N=2384
prevalence= 37.2%
>=1 cigarette per day
>=6 glasses alcohol per week & 
>=drinking a few times per week
ever use of cannabis (for adolescents 
only)
N=970
Prevalence=62.6%
Problematic poly use 
Problematic use of at 
least two substances 
over time
FTNDa score of >=6
CAGE score of >=2
regular cannabis use
N=2376
prevalence=2.4%
FTND score of >=6
RAPI score of >=8
regular cannabis use (for 
adolescents only)
N=1091
Prevalence=4.3%
Education levelb
−	 low: medium vocational school, 
higher secondary school or lower
−	 high: higher vocational school/ 
university
N=2366
prevalence low=50.1%
 
−	 Low: medium vocational school, 
higher secondary school or lower
−	 High: higher vocational school/ 
university
N=1171
Prevalence low=42.5% 
 
aFTND=Fagerström Test of Nicotine Dependence; CAGE=alcohol problems questionnaire; RAPI=Rutgers Alcohol Problem Index
bExplained in the exploratory analyses
cFollowing definitions from Centraal Bureau voor de Statistiek [1]
d Following guidelines from Gezondheidsraad [64]. Drinking at least one glass per day corresponded to the answering category of drinking at 
least 6-10 glasses per week combined with drinking at least a few times per week
Table 2. Overview of aggregate measures included in the main and exploratory analyses, with corresponding cut-off points (if applicable) 
and descriptive statistics.
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since three variants were considered. As can be seen in 
Figure 2, power in the NTR sample is sufficient (80%) for 
an explained variance of approximately 0.4% or more. In the 
F&H sample, a larger effect size of 0.8% would be required 
to have an 80% chance of detecting the effect. 
Results
Descriptive statistics for the predictor and outcome 
variables were given in Table 2. The HPRSs were normally 
distributed between 0 and 2 with a mean of 0.81 and 0.76, 
suggesting that the risk alleles were somewhat rarer than 
the non-risk alleles. In the NTR, 36% had ever smoked on 
a daily basis, 55% had drunk regularly, and 28% had used 
cannabis. In the F&H, these rates were 49%, 83% and 41% 
(for adolescents only), respectively. Using one substance 
on a moderate level predicted the use of another substance 
on a moderate level (χ2=111.9, p<0.01 for NTR; χ2=16.6, 
p<0.01 for F&H). Likewise, the problematic substance use 
phenotypes were significantly related (χ2=29.1, p<0.01 for 
NTR; χ2=43.0, p<0.01 for F&H), justifying the aggregation 
in the polysubstance use indices.
Main effects
There was no relationship between the HPRS and 
moderate or problematic polysubstance use in either sample 
(Table 3). In all models, there was a main effect of sex, such 
that males were more likely than females to show moderate 
and problematic polysubstance use. Results did not change 
when analyses were conducted separately for males and 
females or for young and old cohorts, or when the interactions 
with these factors were included in the analyses (data not 
shown). Effects of age were significant in some models, but 
the coefficients were small and in opposing directions for the 
samples.
Exploratory analyses
Below, possible explanations for the initial null findings 
are examined. Because of the post hoc nature of these tests, 
which increases the multiple testing burdens, a stricter α-level 
of 0.01 was adopted for the exploratory analyses.
Extended risk score
As a possible explanation, it was investigated whether 
a more extensive measure of hypodopaminergic risk could 
predict polysubstance use. The HPRS was extended (eHPRS) 
using risk alleles in other available polymorphisms that 
have shown a relation with hypodopaminergic function and 
substance use (Table 4). Four additional polymorphisms (in 
the genes DRD5, OPRM1, COMT, MAOA) were selected in 
the NTR, and one (in OPRM1 gene) in the F&H sample. The 
eHPRS was calculated if data for at least five (in the NTR 
sample) or four polymorphisms (in the F&H sample) were 
available. Results showed no effect of the eHPRS on either 
outcome (Supplementary Table S1).
Gene-environment interaction
Possibly, the effect of the HPRS was obscured by an 
interaction with environmental influences. If genetic risk 
would lead to more polysubstance use in one environmental 
group, but to lower polysubstance use in another, the main 
effect would not be found in the combined group. One 
plausible environmental variable is socioeconomic status, of 
Figure 2. Power analysis. Power for main analysis in NTR (panel a) and F&H sample (panel b). In the NTR sample, sample sizes for both 
outcomes were very similar, so that power was estimated for both outcomes together. Estimations of effect sizes are in percentage of explained 
variance (R2). An α-level of 0.05 was used.
Moderate poly-substance use Problematic poly-substance use
Predictor b (SD) p b (SD) p
NTR
N=2384 (moderate)
N=2376 (problematic)
HPRS 0.02 (0.13) 0.91 -0.02 (0.43) 0.96
age -0.02 (0.00) <0.01** -0.01 (0.01) 0.30
sex -0.50 (0.09) <0.01** -0.71 (0.28) 0.01*
F&H
N=970 (moderate)
N=1091 (problematic)
HPRS -0.19 (0.22) 0.39 -0.18 (0.48) 0.71
age 0.05 (0.01) <0.01** -0.04 (0.01) <0.01**
sex 0.57 (0.13) <0.01** 1.49 (0.36) <0.01**
*significant at α=0.05 **significant at α=0.01
Table 3. Results for main analyses using the core hypodopaminergic polygenic risk score.
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which education level is an important element. For example, 
it has been found that individuals with a higher education 
level have a lower risk for alcohol problems, so that they will 
not develop those unless they have a high genetic liability, 
whereas environmental risk is more important for individuals 
with a low education level [40]. In both the NTR and F&H 
sample, information on education level was available. 
For individuals under age 25, who may not have finished 
their education, parental education was used as a proxy for 
socioeconomic status. Education level was dichotomized 
using cut-offs as described in Table 2. The interaction of 
education level with the HPRS was explored. 
Results of these analyses are summarized in Table 5. In 
the NTR sample, no significant main or interaction effects 
for education were observed. In the F&H, there was a trend 
for an interaction effect (p=0.03), such that a higher HPRS 
predicted less substance use, but only for persons with a low 
education level. 
Relation between HPRS and separate substances
Possibly, the risk score shows no association with an 
aggregate measure of polysubstance use, but does show 
an association with separate substance use types. If the 
association with separate substances would be in opposing 
directions, they would cancel each other out in the aggregate 
measure. To test this possibility, six GEE analyses were 
conducted for the substance use variables separately 
(moderate and problematic nicotine, alcohol, and cannabis 
use). No significant relations were found, although there 
was a trend in the NTR sample for moderate alcohol use 
in the direction opposite from what was expected (p=0.03) 
(Supplementary Table S2). 
Relation between polysubstance use and separate 
polymorphisms
In the interaction model a negative effect was found of the 
HPRS on substance use. Therefore, it is possible that the risk 
alleles were not correctly selected based on the literature. To 
investigate this possibility, separate GEE analyses for each 
individual genetic variant were conducted. The results are 
summarized in Supplementary Tables S2 and S3. There were 
only two associations significant at the α=0.01 level, both in 
the NTR sample, between MAOA and moderate cannabis use 
and problematic alcohol use. There were as many variants 
with small positive as with small negative coefficients, so 
that these cancelled each other out in the sum score. Sample 
sizes for separate polymorphisms were smaller, so that these 
analyses may have been underpowered.
Gene Polymorphism Risk allele Dopamine-related effect of risk allele
Research findingsb
Supportive Opposing
DRD5
Dopamine 
receptor d5 gene
5’-di-nucleotide 
repeat VNTR 148bp Non-functional
a
Smoking: Sullivan et al. [65]
Substance dependence: Vanyukov et 
al. [66]
         
OPRM1
µ-opioid receptor 
gene
rs1799971 A118G 
SNP G Reduced release
Smoking: Kleinjan et al. [67]
Alcohol: Miranda et al. [68]
Drug dependence: Zhang et al. [69]
Alcoholism: Du and Wan [70]
Alcoholism and polysubstance abuse: Schinka 
et al. [71] 
COMT 
Catechol-O-
methyltrans-
ferase gene
rs4680
Val158Metb SNP G (Val)
Increased 
catabolism
Smoking: Munafo et al. [56]
Alcoholism: Enoch et al. [72]
Cannabis: Isir et al. [73]
Smoking: Beuten et al. [74] 
Alcohol: Hendershot et al. [75]
Cannabis: Verdejo-García et al. [76] 
MAOA
Monoamine 
oxidase-A gene
promoter 30bp 
VNTRa
long (>=3.5 
repeats)
Increased 
catabolism
Smoking: Wiesbeck et al. [77]
Alcohol: Nilsson et al. [78]
Drug abuse: Gade et al. [79]
Smoking: Jin et al. [80] 
Alcohol: Samochowiec et al. [81] 
Substance use disorders: Vanyukov et al. [82]
aThe DRD5 polymorphism is likely to be in linkage disequilibrium with variants that decrease dopamine receptor 1 efficiency 
bA positive research finding indicates that a positive relation was found between the risk allele and substance use; an opposing finding 
indicates a positive relation between the non-risk allele and substance use
cNon-European ancestry study sample (i.e., Asian, Indian-American)
Table 4. Summary of polymorphisms in more peripherally dopamine-related genes that were included in the explorative hypodopaminergic 
polygenic risk score (eHPRS). 
Moderate poly-substance use Problematic poly-Substance use
Predictor b (SD) p b (SD) p
NTR
N=2315 (moderate)
N=2312 (problematic)
HPRS -0.05 (0.40) 0.81 -0.19 (1.23) 0.85
Age -0.02 (0.00) <0.01** -0.01 (0.01) 0.32
Sex -0.52 (0.09) <0.01** -0.71 (0.29) 0.02*
Education -0.16 (0.10) 0.10 -0.49 (0.30) 0.11
HPRS*education 0.06 (0.25) 0.81 0.15 (0.78) 0.85
F&H
N=969 (moderate)
N=1090 (problematic)
HPRS -1.88 (0.80) 0.02* -2.81 (1.49) 0.06
Age 0.05 (0.01) <0.01** -0.04 (0.01) <0.01
Sex 0.58 (0.13) <0.01** 1.49 (0.36) <0.01**
Education -0.16 (0.17) 0.33 -0.33 (0.36) 0.35
HPRS*education 1.05 (0.47) 0.03* 1.73 (0.91) 0.06
*significant at α=0.05 ** significant at α=0.01
Table 5. Results for main analyses using the core hypodopaminergic polygenic risk score including the main and interaction effect of family 
education level.
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Quadratic effects
Both positive and negative coefficients were found 
for separate polymorphisms and separate substance use 
outcomes. Possibly, low and high (rather than normal) 
dopamine functions are predictive of substance use. To test 
this possibility, the squared centered HPRS was added as a 
predictor in the model. This quadratic term was zero when 
a person had an average number of hyperdopaminergic risk 
alleles, and increased when he/she had a high or low number 
of alleles. Analyses using this quadratic term revealed no 
significant associations (Supplementary Table S4).
Discussion
This study aimed to test the association between three 
hypodopaminergic genetic variants and the use of multiple 
substances over life. In two samples, the hypodopaminergic 
polygenic risk score did not predict polysubstance use and 
this did not change when additional polymorphisms were 
included. 
Possible explanations
Several explanations for the null results can be offered. 
First, although there was sufficient power to detect an effect 
of at least R2=0.4-0.8%, it could be that the true effect 
size was smaller than that. Also, power in the problematic 
polysubstance use analyses might have been compromised 
by the low prevalence of this phenotype. 
As a second explanation, an interaction between genetic 
vulnerability and an environmental factor could have 
muddled the results. It has been suggested that interaction 
with environmental variables is one of the reasons why 
molecular genetics studies succeed in explaining only small 
part of the heritability estimates found in twin studies [41]. 
A plausible candidate for such an environmental variable is 
socioeconomic status, often indexed by (parental) education 
level. For example, it has been found that genetic factors are 
more important for people with a high education level than 
for those with a low education level in determining the risk 
for alcohol problems [40]. However, the null-results were 
not explained by an interaction with family education level, 
although there were some unexpected trends in the F&H 
dataset, showing a stronger negative relation between genetic 
risk and substance use for persons with a low education level. 
Third, it might be that the genetic risk scores had 
opposing effects on the different substance use types, thus 
obscuring a main effect. This could be driven by one or more 
polymorphisms that have shown associations in opposing 
directions for different substances. As we tested this, however, 
the polygenic risk scores showed hardly any relations with the 
substance use variables separately, rendering this explanation 
insufficient. 
As a fourth explanation, it was tested whether 
individual polymorphisms had opposing effects. Selection 
of hypodopaminergic alleles related to substance use was 
based on an extensive literature search, but reports were not 
consistent. Indeed, in both samples, the selected risk alleles 
showed both positive and negative relations with substance 
use phenotypes, suggesting that they canceled each other out 
in the combined scores. However, these individual effects 
were not significant. This is in line with many studies that did 
not find an effect of individual variants in dopamine-related 
genes on substance use [26,42-44], but in conflict with an 
even larger number of studies that did find an effect in the 
direction that was hypothesized or an effect in the opposing 
direction (Tables 1 and 4).
Finally, it was investigated if there was a quadratic effect 
of the risk score. This would mean that both hypo- and hyper-
dopaminergic alleles predict polysubstance use, in contrast to 
alleles related to normal dopaminergic function. Considering 
the opposing effects found for the candidate genes (Tables 1 
and 4) this is a plausible explanation. Also, of the two studies 
to our knowledge that used a dopaminergic polygenic risk 
score similar to the one in the current investigation, one found 
an effect of hypodopaminergic alleles on substance use [15], 
but the other found a relation between a hyperdopaminergic 
alleles and addiction [16]. However, tests of a quadratic term 
in our study did not suggest that low and high numbers of 
hypodopaminergic alleles were predictive of polysubstance 
use as compared to average numbers of alleles. 
Concluding, we could not sufficiently explain the null-
results with post hoc tests. This suggests that risk alleles in 
dopamine-related genes do not play a vital role in predicting 
polysubstance use. Indeed, large GWAS for substance use 
phenotypes [45-47] have rarely identified dopamine-related 
polymorphisms as their top results, suggesting that these 
may not be as important as has traditionally been assumed. 
This might mean that the relation with dopamine function is 
more indirect. For example, a variation in the CHRNA5 gene 
(rs16969968) related to smoking addiction reduces nicotine 
receptor activity, which may hamper the eventual dopamine 
response to nicotine [48]. Alternatively, the genetic etiology 
of substance use may lie more in other mechanisms than 
dopamine function, such as the metabolism of the substance. 
For example, there are indications that variants in the alcohol 
dehydrogenase (ADH) gene cluster that are related to 
impaired alcohol metabolism lower the chances of alcohol 
dependence [49].
Strengths and limitations
This study aimed to tackle limitations of previous research. 
We used a design with polygenic risk scores and aggregate 
outcome measures in order to counteract power-problems 
associated with candidate-gene studies. Indeed, power was 
sufficient to detect reasonably small effect sizes. A second 
strength was that we replicated the analyses in a separate 
sample, which is paramount for genetic association studies 
[50]. Also, we included VNTRs, that have as of yet not been 
investigated in GWAS. Furthermore, the longitudinal nature 
of the data increased chances of reliably capturing substance 
use. Finally, we tested several explanations for our results, 
which give some indication for the reliability of our findings.
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An important limitation of this study lies in the 
identification of the genetic risk variants based on their 
proposed relation with hypodopaminergic function, although 
effects in other directions were explored. We restricted 
ourselves to genes for which a relation had been found, rather 
than genes that are in the same pathway but for which a clear 
effect on dopamine levels has not yet been revealed. 
The use of an aggregated outcome measure might be 
viewed as a strength (as it should increase power to detect 
effects), but might also have introduced heterogeneity. 
Preliminary tests of the association among the separate 
substance use measures however suggested that aggregating 
them was sensible. Also, relations between the HPRS with 
separate substance use variables were explored and testing 
an aggregate measuring use of no versus 1 or more substance 
did not change results (not shown). The fact that only 
adolescent cannabis use was available in the F&H sample is 
unlikely to have biased the results, as the same results were 
obtained in the NTR sample, where adults were included in 
the measure. The measure of problematic cannabis use was 
based on one question measuring ‘regular’ use, which may 
not reliably capture problematic use. Still, it has been found 
that approximate measures of regular cannabis use (e.g. 
having used at least ten times) already predict later abuse and 
dependence [51]. 
Conclusions and Future Directions
We found a sum score of hypodopaminergic risk alleles 
to be unrelated to moderate and problematic polysubstance 
use. The most likely explanation for these findings seemed 
to be that these polymorphisms do not play a crucial role in 
substance use phenotypes. Future research might include (non-
SNP) polymorphisms unrelated to dopamine, or might adopt 
a hypothesis-free approach to circumvent the difficulty with 
defining risk alleles. Also, studies should include a role for 
gene-environment interaction, as there were indications that this 
may alter results. Time may be right for more complex genome-
wide models, where interaction, mediation, gene-environment 
correlation, and opposing effects are included to disentangle the 
relation between dopamine-related genes and substance use.
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